Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

184.02 +2.34 (+1.29%)
Official Closing Price Updated: 7:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
80 81 Next >
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people. 
Via Benzinga
Topics Government
Exposures Political
A Glimpse Into The Expert Outlook On AbbVie Through 15 Analysts
Via Benzinga
I Own 4 High-Yield Dividend Stocks. Here's Why I Own Each One.
Via The Motley Fool
Why AbbVie Stock Popped While the Market Flopped on Monday
Via The Motley Fool
AbbVie Builds Momentum With Immunology Growth, Goldman Remains Positive
AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth remains a key focus for investors. 
Via Benzinga
$1000 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Unpacking the Latest Options Trading Trends in AbbVie
Via Benzinga
AbbVie Unusual Options Activity For January 10
Via Benzinga
Biotech And Healthcare Stocks Poised For Gains Ahead
The XLV bounced off the bottom this month up 4% to the $144 level led by biopharma and medtech. 
Via Talk Markets
Topics ETFs Stocks / Equities
Is AbbVie Stock a Buy?
Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better. 
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
Got $1,500? 3 Healthcare Stocks to Buy and Hold Forever
Via The Motley Fool
Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why
The company expects to soon expand from a single-product player to a "multi-product innovator." 
Via Investor's Business Daily
Got $500? 2 Pharmaceutical Stocks to Buy and Hold Forever
Via The Motley Fool
3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever
Via The Motley Fool
Assessing AbbVie: Insights From 17 Financial Analysts
Via Benzinga
Here's How Much $1000 Invested In AbbVie 5 Years Ago Would Be Worth Today
Via Benzinga
Healthcare And Biotech Stocks Lag The Market Again
Biotech stocks got little help from the JPM Conference despite some recovery to the general market. 
Via Talk Markets
Topics Stocks / Equities
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company. 
Via Benzinga
Topics Government
Exposures Political
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Top Research Reports For Visa, AbbVie & Analog Devices
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc., AbbVie Inc., Analog Devices, Inc. (ADI), and a micro-cap stock Precipio, Inc. 
Via Talk Markets
Topics Stocks / Equities
10 One Decision Stocks To Buy Now
The following 10 one decision stocks have increased their dividends for over 25 years, making them Dividend Aristocrats. 
Via Talk Markets
Topics Stocks / Equities
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
2 Brilliant Dividend Growth Stocks That Can Supercharge Your Portfolio
Via The Motley Fool
3 High-Yielding Dividend Stocks That Could Be Ideal Investments for Retirees
Via The Motley Fool
Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal
Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies boosts its CNS portfolio with Caplyta and a promising clinical-stage pipeline. 
Via Benzinga
3 High-Yield Dividend Stocks to Buy in 2025
Via The Motley Fool
3 Incredible Dividend Stocks to Buy in 2025
These wildly successful companies are poised to keep your dividend portfolio healthy in 2025 and beyond. 
Via The Motley Fool
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
The Smartest Dividend Stocks to Buy With $500 Right Now
Some prominent healthcare and consumer stocks have fallen out of favor with the market, so now is the time to pounce on some great deals. 
Via The Motley Fool
25 Top Dividend Stocks to Buy and Hold in 2025
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
80 81 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS